Investing.com -- BeiGene (NASDAQ: ONC ), a global oncology firm, has been granted an Orphan Drug Designation by the FDA for its drug sonrotocla, intended for the treatment of myelodysplastic syndromes. This approval is a significant step for BeiGene in its mission to develop innovative, affordable, and accessible treatments for cancer patients worldwide.

The company, which is in the process of changing its name to BeOne Medicines Ltd., is known for its extensive portfolio of potential treatments. BeiGene is accelerating the development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The firm is dedicated to drastically improving access to medicines for a larger number of patients who require them.

BeiGene’s global team, which numbers nearly 11,000 colleagues, extends across five continents. The company’s commitment to discovering and developing innovative treatments is reflected in its broad portfolio, which is being expedited through both internal capabilities and collaborations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.